Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

OG-6219

Small molecule

Phase 2 Most advanced trial (none active)
1 Registered trials

What is OG-6219?

OG-6219 is an investigational small-molecule drug studied in Endometriosis.

At a glance

Drug type
Small molecule
Therapy area
Renal & urology
In trials of
IQV
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
PP3PLL7GZY

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05560646 Phase 2 Endometriosis Completed IQV

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Endometriosis

Sources

Updated Oct 3, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.